Public Employees Retirement System of Ohio Buys New Stake in Bausch Health Cos Inc. $BHC

Posted by Geri Gentry on Sep 6th, 2026

Public Employees Retirement System of Ohio purchased a new position in Bausch Health Cos Inc. (NYSE:BHC – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 520,609 shares of the company’s stock, valued at approximately $2,565,000.

Other large investors have also made changes to their positions in the company. Paulson & CO. Inc. purchased a new stake in shares of Bausch Health Cos during the second quarter worth about $361,151,000. Dimensional Fund Advisors LP raised its position in shares of Bausch Health Cos by 10.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,604,818 shares of the company’s stock valued at $19,456,000 after purchasing an additional 350,823 shares during the last quarter. MFN Partners Management LP purchased a new position in shares of Bausch Health Cos in the 2nd quarter valued at approximately $29,580,000. Royal Bank of Canada boosted its stake in Bausch Health Cos by 24.9% in the 1st quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock worth $61,362,000 after purchasing an additional 2,262,894 shares in the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new stake in Bausch Health Cos during the 4th quarter worth approximately $3,651,000. 78.65% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on BHC shares. Zacks Research upgraded shares of Bausch Health Cos from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. Jefferies Financial Group raised shares of Bausch Health Cos to a “hold” rating in a report on Wednesday, July 22nd. Weiss Ratings raised Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, July 31st. Finally, Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Six equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $8.00.

Check Out Our Latest Stock Report on BHC

Bausch Health Cos Price Performance

NYSE:BHC opened at $6.54 on Friday. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.44 and a quick ratio of 1.08. The company has a 50 day moving average price of $5.70 and a 200-day moving average price of $5.51. Bausch Health Cos Inc. has a 1-year low of $4.33 and a 1-year high of $8.00. The firm has a market cap of $2.45 billion, a price-to-earnings ratio of -2.21 and a beta of 0.37.

Bausch Health Cos (NYSE:BHC – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.30. The firm had revenue of $2.83 billion during the quarter, compared to analyst estimates of $2.59 billion. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. Equities research analysts forecast that Bausch Health Cos Inc. will post 4.35 EPS for the current year.

Insiders Place Their Bets

In other news, insider Aimee Lenar sold 36,827 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total transaction of $258,893.81. Following the transaction, the insider directly owned 334,853 shares in the company, valued at $2,354,016.59. The trade was a 9.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.67% of the company’s stock.

Bausch Health Cos Company Profile

(Free Report)

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.